Australia markets closed

Virios Therapeutics, Inc. (VIRI)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
6.21-0.15 (-2.36%)
At close: 03:59PM EST
6.57 +0.35 (+5.63%)
After hours: 04:14PM EST

Virios Therapeutics, Inc.

44 Milton Avenue
Alpharetta, GA 30009
United States
866 620 8655
https://www.virios.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees3

Key executives

NameTitlePayExercisedYear born
Mr. Greg DuncanChairman & CEO779.32kN/A1965
Ms. Angela WalshCFO, SVP of Fin., Corp. Sec. & Treasurer253.45kN/A1967
Mr. Ralph D. Grosswald M.P.H.Sr. VP of Operations233.95kN/A1969
Ms. Carol Duffy Ph.D.Chief Scientific AdvisorN/AN/AN/A
Dr. R. Michael GendreauChief Medical OfficerN/AN/A1956
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia.

Corporate governance

Virios Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.